Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576631 | 0.84 | PKM (0.65) | PKMSMN1; SMN2TSHRPTGDR2HSD17B10 | |
| SCHEMBL23949850 | 0.79 | PKM (0.55) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30353364 | 0.79 | PKM (0.55) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL1343423 | 0.79 | PKM (0.73) | PKMSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL19584786 | 0.76 | PTGDR2 (0.49) | PKMSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL7881748 | 0.74 | PKM (0.43) | PKMSMN1; SMN2TSHRMAPTALDH1A1 | |
| SCHEMBL1265343 | 0.74 | PKM (0.45) | PKMTSHRPTGDR2L3MBTL1SLC1A3 | |
| SCHEMBL16579856 | 0.72 | PKM (0.41) | PKMSMN1; SMN2HPGDTSHRGAA | |
| SCHEMBL1136112 | 0.72 | HPGD (0.39) | SMN1; SMN2NPC1RAB9AHPGDGAA | |
| SCHEMBL12634713 | 0.72 | SLC6A4 (0.40) | PKMSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509494-B1 | AMIDOACETONITRILE COMPOUNDS AGAINST PARASITES | NOVARTIS AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-7446219-B2 | N-acylaminoacetonitrile derivatives and their use for controlling parasites | NOVARTIS ANIMAL HEALTH US INC. (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1509221-B1 | N-ACYLAMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7148255-B2 | Amidoacetonitrile compounds | NOVARTIS ANIMAL HEALTH US, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050203148-A1 | Organic compounds | NOVARTIS ANIMAL HEALTH US, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050182127-A1 | N-acylaminoacetonitrile derivatives and their use for controlling parasites | NOVARTIS ANIMAL HEALTH US, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1509221-A1 | N-ACYLAMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| EP-1509494-A2 | AMIDOACETONITRILE COMPOUNDS | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097036-A1 | N-ACYLAMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097585-A2 | AMIDOACETONITRILE COMPOUNDS | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203148-A1 | Organic compounds | AOX1, ADORA2B, ACHE | PKM 2441/4885SMN1; SMN2 2550/4885NPC1 3697/4885 |
| US-20050182127-A1 | N-acylaminoacetonitrile derivatives and their use for controlling parasites | NAT1, AANAT, ACHE | PKM 1572/4885SMN1; SMN2 1491/4885NPC1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.